Posted by Two Blokes
Company announcement – No. 17 / 2025 Zealand Pharma major shareholder announcement: Van Herk Investments B.V.
Source: Two Blokes Trading
Posted by Two Blokes
Shelagh Glaser, CFO of Synopsys (SNPS), talks about the company's recent acquisition of Ansys. She believes it
Source: Two Blokes Trading
Posted by Two Blokes
A WSJ survey shows less pessimism regarding the second quarter. Uncertainty over trade policy and immigration
Source: Two Blokes Trading
Posted by Two Blokes
TAP leans into premium brands like Peroni and Madri to lift margins. Yet, volume declines remain a hurdle.
Source: Two Blokes Trading
Posted by Two Blokes
Rocket Pharmaceuticals jumps 16.8% as FDA grants RMAT status to RP-A601 on positive phase I heart disease data
Source: Two Blokes Trading
Posted by Two Blokes
ET outpaces its industry with strong pipeline assets, strategic deals, and fee-based earnings driving steady g
Source: Two Blokes Trading
Posted by Two Blokes
DHR's Q2 results are likely to reflect Life Sciences weakness, but strength in Biotechnology & Diagnostics uni
Source: Two Blokes Trading
Posted by Two Blokes
Netflix Inc (NASDAQ:NFLX, ETR:NFC) delivered another blockbuster quarter, beating estimates and raising its fu
Source: Two Blokes Trading
Posted by Two Blokes
If you wonder whether Abbott Laboratories NYSE: ABT is a good buy in Q2 2025, the answer is yes. The company's
Source: Two Blokes Trading
Posted by Two Blokes
KDP's Q2 results are likely to reflect benefits from strong beverage demand, GHOST acquisition gains and innov
Source: Two Blokes Trading
Posted by Two Blokes
As a result of three big crypto bills passing in the US House and a daily spike in Bitcoin, Ether, and XRP, am
Source: Two Blokes Trading
Posted by Two Blokes
LTC has finally broken out of weeks of sideways action, closing above a key resistance zone.
Source: Two Blokes Trading